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Abstract 
Objective: Cytoplasmic microinjection and electroporation of the CRISPR/Cas9 system into zygotes are used for 
generating genetically modified pigs. However, these methods create mosaic mutations in embryos. In this study, we 
evaluated whether the gene editing method and embryonic stage for gene editing affect the gene editing efficiency 
of porcine embryos.
Results: First, we designed five guide RNAs (gRNAs) targeting the B4GALNT2 gene and evaluated mutation efficiency 
by introducing each gRNA with Cas9 protein into zygotes by electroporation. Next, the optimized gRNA with Cas9 
protein was introduced into 1-cell and 2-cell stage embryos by either microinjection or electroporation. The sequence 
of gRNA affected the bi-allelic mutation rate and mutation efficiency of blastocysts derived from electroporated 
embryos. Microinjection significantly decreased the cleavage rates in each embryonic stage and blastocyst forma-
tion rates in 2-cell stage embryos compared with electroporation (p < 0.05). However, the bi-allelic mutation rate and 
mutation efficiency of blastocysts from the 1-cell stage embryos edited using microinjection were significantly higher 
(p < 0.05) than those of blastocysts from the 2-cell stage embryos edited by both methods. These results indicate that 
the gene editing method and embryonic stage for gene editing may affect the genotype and mutation efficiency of 
the resulting embryos.
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Introduction
Genetically modified pigs are expected to be an excel-
lent disease model contributing to human medicine [1, 2] 
and to be ideal organ donors for human xenotransplan-
tation [3, 4]. The clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-associated gene 
(CRISPR/Cas) system has been recently used to gener-
ate gene-modified animals carrying site-specific muta-
tions by delivering the Cas9/gRNA complex into the 
embryos mostly via microinjection [5–7]. However, the 
genotype of the mutant embryos often exhibits a mosaic 
pattern, i.e. these mutant embryos are composed of sev-
eral types of cells with different mutations [8–11]. In our 
previous study, we developed the GEEP (gene editing by 
electroporation of Cas9 protein) method that enabled 
disruption of the targeted genes with high-efficiency in 
pigs by introduction of CRISPR/Cas9 system into zygotes 
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damage associated with micromanipulation, however, 
also induces the mosaic pattern in the embryos [13]. The 
occurrence of genetic mosaics including wild-type (WT) 
cells complicates the analysis of phenotype in the result-
ing pigs, therefore mosaicism is a serious problem.
It has been suggested that mosaic mutants arise due 
to Cas9/gRNA complexes that remain active through-
out several cell divisions, or delayed mRNA expression, 
possibly triggered by cell division [11]. The continuous 
function of Cas9 on the targeting site during embryonic 
development induces the mosaic phenomenon of modi-
fication. On the other hand, the generation of mosaic 
mutants by introduction of Cas9 protein/gRNA com-
plexes into 1-cell stage embryos depends on the time 
window between fertilization and the first DNA replica-
tion [14]. Moreover, Gu et  al. [15] suggested that major 
zygotic genome activation with an open chromatin state 
occurs during the extended G2 phase of the 2-cell stage 
embryos, resulting in decreased mosaic phenomenon 
after gene editing by the CRISPR/Cas9 system.
β-1,4-N-acetyl-galactosaminyltransferase 2 
(B4GALNT2) synthesizes carbohydrate xenoantigens, 
which account for the majority of human anti-pig anti-
body reactivity [16]. The generation of B4GALNT2-defi-
cient animals appears to be a necessary step in achieving 
successful pig-human xenotransplantation. In the pre-
sent study, to reduce the mosaic mutation in the early 
embryos, we evaluated the developmental competence 
and gene editing efficiency of porcine embryos at the 
1-cell and 2-cell stage after introduction of the complexes 
of Cas9 protein and gRNA targeting the B4GALNT2 gene 
by microinjection or electroporation methods.
Main text
Materials and methods
Oocyte collection, in vitro maturation(IVM) and in vitro 
fertilization (IVF)
Oocyte collection, IVM and IVF were performed as 
described previously [17]. Briefly, pig ovaries were 
obtained from prepubertal crossed gilts at a local slaugh-
terhouse. Cumulus-oocyte complexes (COCs) were col-
lected and cultured in maturation medium. After IVF, the 
putative zygotes were cultured in porcine zygote medium 
(PZM-5; Research Institute for the Functional Peptides 
Co., Yamagata, Japan) until microinjection and elec-
troporation treatments.
Electroporation
Electroporation was performed as described previously 
[12]. Briefly, embryos were electroporated (five 1-ms 
pulses at 25 V) with Nuclease-Free Duplex Buffer (Inte-
grated DNA Technologies, Coralville, IA, USA) contain-
ing 100  ng/μl of gRNA (Alt-R™ CRISPR crRNAs and 
tracrRNA) (Integrated DNA Technologies) and 100  ng/
µl Cas9 protein (Takara Bio, Inc., Shiga, Japan). After 
electroporation, the embryos were cultured in PZM-
5. At Day 3 after fertilization (Day 0), all of the cleaved 
embryos were subsequently cultured in porcine blasto-
cyst medium (PBM; Research Institute for the Functional 
Peptides Co.) for 4 days.
Cytoplasmic microinjection
The CRISPR/Cas9 components were injected into 1-cell 
and 2-cell stage embryos in a 20 μl drop of PZM-5 cov-
ered by mineral oil. The duplex buffer containing 100 ng/
μl of gRNA and 100 ng/μl of Cas9 protein was loaded into 
the injection pipette (Femtotips II, Eppendorf, Hamburg, 
Germany) and injected into the cytoplasm by air pressure 
using a microinjector (FemtoJet 4i; Eppendorf ). After 
microinjection, the embryos were cultured in PZM-5 and 
PBM as described above.
Analysis of targeted gene sequence after microinjection 
and electroporation
Genomic DNA isolated from resulting blastocysts col-
lected individually were subjected to polymerase chain 
reaction (PCR) using the specific primers (Additional 
file  1: Table  S1). The PCR products were analyzed by 
Sanger sequencing and the TIDE (tracking of indels by 
decomposition) bioinformatics package [18] as described 
previously [19]. Blastocysts were classified as having bi-
allelic mutations (carrying no WT sequences), mosaics 
(carrying more than one type of mutation and the WT 
sequence), or WT (carrying only the WT sequence).
Experimental design
Experiment 1: Comparison of gRNA gene‑targeting efficiency
To confirm the optimal gRNA for efficient gene edit-
ing, we designed five gRNAs (#1–#5) targeting different 
sites of the B4GALNT2 gene (Additional file 2: Table S2). 
Each gRNA and Cas9 protein were introduced into por-
cine embryos by electroporation at 12 h after the start of 
IVF. The blastocyst formation rate from the embryos post 
introduction of each gRNA and the mutation efficiency 
in the resulting blastocysts were evaluated, as described 
above. As a control, some embryos were cultured with 
PZM-5 and PBM for 7  days without electroporation 
treatment.
Experiment 2: Comparison of the development stage 
and gene editing method
Embryos at the 1-cell and 2- cell stages were collected 
at 12  h and 24  h after the start of IVF, respectively. 
gRNA #1, which was confirmed by Experiment 1 to 
show high-efficiency targeting of B4GALNT2 gene, was 
used in Experiment 2. Cas9 protein with gRNA #1 was 
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introduced into the embryos at each stage by microinjec-
tion and electroporation. For the 2-cell stage embryos, we 
injected Cas9 protein with gRNA into both blastomeres, 
separately. As a control, the embryos at the 1-cell and 
2-cell stages were microinjected and electroporated with-
out gRNA and Cas9. After the in vitro culture, the result-
ing blastocysts were collected and subjected to analysis of 
genotype, as described above.
Statistical analysis
All percentage data were subjected to arcsine transfor-
mation before performing analysis of variance (ANOVA). 
The transformed data were tested by ANOVA, followed 
by Fisher’s protected least significant difference test, 
using StatView software (Abacus Concepts, Berkeley, 
CA, USA). The percentages of mosaic and bi-allelic blas-
tocysts in the total number of blastocysts were analyzed 
by chi-squared analysis with Fisher’s exact test. Differ-




Representative images of the genotyping are shown in 
Additional file 3: Figure S1. There were no significant dif-
ferences in the cleavage and blastocyst formation rates 
of embryos edited by electroporation among the differ-
ent gRNA groups (Fig. 1a, b). The total mutation rate of 
Fig. 1 Introduction of the CRISPR/Cas9 system targeting the B4GALNT gene into embryos by electroporation. a Cleavage and b blastocyst 
formation rates of electroporated embryos. Five replicates were analyzed for each treatment group. c Genotype of blastocysts, determined using 
Sanger sequencing and TIDE analysis. The proportions were calculated by dividing the number of gene-edited (bi-allelic and mosaic) blastocysts 
by the total number of sequenced blastocysts. bi: blastocysts having bi-allelic mutations, mos: blastocysts having mosaic mutations. d Mutation 
efficiency of gene-edited blastocysts. The mean proportions represent the proportion of indel mutation events in gene-edited blastocysts. The 
numbers within parentheses under the X-axis indicate the total number of examined samples. Error bars indicate mean ± SEM (a, c). a−c, A−CBars 
with different letters differ significantly (P < 0.05)
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blastocysts derived from the embryos electroporated 
with gRNA #4 significantly increased (p < 0.05) compared 
with that with gRNAs #2 and #5 (Fig. 1c). The bi-allelic 
mutant rate of blastocysts from embryos electroporated 
with gRNA #1 was significantly higher (p < 0.05) than 
that with gRNAs #2 and #5. Moreover, the mutation effi-
ciency in gene-edited blastocysts derived from embryos 
electroporated with gRNA #1 significantly increased 
(p < 0.05) compared with that with gRNAs #2 and #3 
(Fig. 1d).
Experiment 2
As shown in Table  1, the cleavage rates of embryos 
treated using the microinjection method significantly 
decreased compared with those of embryos treated using 
the electroporation method, irrespective of the embry-
onic stage (p < 0.05). The blastocyst formation rate of 
1-cell stage and 2-cell stage embryos having Cas9 and 
gRNA introduced via microinjection was significantly 
lower (p < 0.05) than that of 2-cell stage embryos having 
gRNA and Cas9 introduced via electroporation. When 
the embryonic stage and gene editing method were 
same, the cleavage rates and blastocyst formation rates of 
embryos treated with gRNA and Cas9 were statistically 
same as that of embryos treated without gRNA and Cas9.
The total mutation rate of blastocysts derived from 
the 2-cell stage embryos edited using the microinjection 
method significantly decreased (p < 0.05) compared with 
that of the other treatment groups (Fig. 2a). The rates of 
bi-allelic mutant and mutation efficiency of blastocysts 
from the 1-cell stage embryos edited using the microin-
jection method were significantly higher (p < 0.05) than 
those of blastocysts from the 2-cell stage embryos edited 
using both methods (Fig. 2a, b).
Discussion
Xenotransplantation is a potential solution to address 
the growing demand for organs suitable for transplan-
tation. B4GALNT2 synthesizes carbohydrate xenoanti-
gen, which is one of the major xenoantigen expressed at 
high levels in porcine tissue but absent in human tissue 
[16]. Therefore, generating B4GALNT2-deficient pigs 
is the first step for achieving successful pig-to-human 
xenotransplantation. To date, highly efficient gene modi-
fication of embryos using the CRISPR/Cas9 system intro-
duced by microinjection and electroporation has been 
reported in experimental animals [6, 12, 20]. However, 
mosaicism including WT cells is a serious problem for 
gene modification by the CRISPR/Cas9 system [21]. One-
step generation of F0 pigs with the completely desired 
gene modification saves cost and time.
We first optimized the gRNA for efficient targeting of 
the B4GALNT2 gene using the electroporation method. 
Although we could not evaluate the quality of blasto-
cysts because we subjected all blastocysts derived from 
electroporated embryos for genotyping, we found that 
the sequence of gRNA used in this study did not affect 
the blastocyst formation rate after the electroporation 
treatment. However, the mutation efficiency of resulting 
blastocysts was affected by the sequence of gRNA. These 
results were supported by previous studies that demon-
strated the design of gRNA to be one of the keys factors 
enabling gene-targeting and mutation efficiency in the 
CRISPR/Cas9 system [22, 23].
Table 1 Introduction of  CRISPR/Cas9 system into  embryos at  different stages by  cytoplasmic microinjection 
and electroporation
MI microinjection, EP electroporation
All of the experiments were repeated four to five times. Data are expressed as the mean ± SEM
* The embryos at the 1-cell and 2-cell stages were microinjected and electroporated with (+) or without (−) gRNA and Cas9 complexes
** The embryos treated at 2-cell stage were defined as cleavage when they have more than 3 blastomeres on day 7
a−c Values with different superscripts in the same column are significantly different (p < 0.05)
Embryonic stage Gene editing 
method




1-cell MI  − 201 138 (68.7 ± 2.6)a 21 (10.5 ± 1.7)a
 + 248 155 (62.4 ± 2.9)a 20 ( 8.1 ± 1.1)a
EP  − 210 192 (91.5 ± 1.7)b 38 (18.1 ± 1.4)ab
 + 250 230 (92.0 ± 0.9)b 40 (16.0 ± 3.1)ab
2-cells MI  − 105 78 (74.3 ± 1.7)a 19 (18.2 ± 1.8)ab
 + 119 73 (61.5 ± 6.2)a 15 (13.4 ± 6.4)a
EP  − 105 91 (86.9 ± 1.9)b 34 (32.6 ± 1.9)c
 + 128 114 (89.7 ± 4.3)b 33 (26.3 ± 7.7)bc
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In Experiment 2, we compared the effects of the gene 
editing method and embryonic stage on the development 
and mutation efficiency of porcine embryos. Our results 
demonstrated that the gene editing method affected 
the cleavage rates. The blastocyst formation rate of the 
2-cell stage embryos electroporated in experiment 2 was 
approximately two times higher than that of the control 
embryos (experiment 1). The higher blastocyst formation 
rate seems to be due to the use of only embryos reach-
ing the 2-cell stage for electroporation. However, the 
mean rates of blastocyst formation in the microinjection 
method decreased to approximately half of that in the 
electroporation method, irrespective of the embryonic 
stage. One possible explanation for the decrease in blas-
tocyst formation rates is that mechanical invasion during 
the microinjection procedure of the CRISPR/Cas9 system 
may reduce the developmental competence of embryos 
[24, 25]. Another cause of reduced embryo develop-
ment may be the amount of expressed protein and tox-
icity that depends on the Cas9 concentration injected. 
However, investigation of embryonic development has 
revealed that injection of 200 ng/µl Cas9 mRNA is non-
toxic to embryos [26]. In the present study, we injected 
only 100  ng/µl Cas9 protein (160  kDa), which is much 
smaller than Cas9 mRNA (~ 1500  kDa), suggesting low 
toxicity. In Experiment 2, the blastocyst formation rate 
was affected by microinjection treatment, but we could 
not evaluate the quality of blastocysts because of geno-
typing analysis. A previous study using parthenogenetic 
embryos demonstrated that cytoplasmic microinjection 
reduced blastocyst formation rate, but the average cell 
number of blastocysts in the microinjected group was 
comparable to that in the untreated control group [27]. 
We guess that the quality of blastocysts derived from 
microinjected embryos may be also comparable to that in 
the control and electroporated group in this study.
Our results demonstrated that the embryonic stage 
effect on the mutation of blastocysts was apparent in the 
microinjection method, in which blastocysts from the 
1-cell stage embryos had higher rates of total mutation, 
bi-allelic mutation, and mutation efficiency compared 
with blastocysts from the 2-cell stage embryos. How-
ever, these results were not consistent with the findings 
of Gu et al. [15], who reported that, in mice, the knock-
in efficiency by 2-cell microinjection of CRISPR reagents 
was higher than that by zygote microinjection. They sug-
gested that major zygotic genome activation, which takes 
place during the extended G2 phase of the 2-cell stage, 
is associated with an open chromatin state, resulting in 
increase of the accessibility of the chromatin to editing 
enzymes and repair templates. In contrast, introduc-
tion of the CRISPR/Cas9 system by electroporation into 
early 1-cell stage embryos prior to or soon after the first 
cleavage divisions has been shown to generate high non-
mosaic mutants in mouse embryos [14]. However, the 
extent of mosaicism varies from embryo to embryo and 
from gene to gene [15]. Therefore, the discrepancy in the 
embryonic stage effects remains to be explained, but it 
might be partly due to the differences in animal species 
or target genes.
Fig. 2 Introduction of the CRISPR/Cas9 system into embryos at different development stages by microinjection and electroporation. a Genotype 
of blastocysts. The proportions were calculated by dividing the number of gene-edited (bi-allelic and mosaic) blastocysts by the total number of 
analyzed blastocysts. bi: blastocysts having bi-allelic mutations, mos: blastocysts having mosaic mutations. b Mutation efficiency of gene-edited 
blastocysts. The mean proportions represent the proportion of indel mutation events in gene-edited blastocysts. The numbers within parentheses 
under the X-axis indicate the total number of examined samples. Error bars indicate mean ± SEM b. a−b, A−CBars with different letters differ 
significantly (P < 0.05). MI: microinjection, EP: electroporation
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The mosaic issue remains to be resolved for genetically 
engineering large animal models. Therefore, to obtain 
highly efficient gene-edited embryos for one-step gen-
eration, microinjection of the CRISPR/Cas9 system into 
1-cell stage embryos may be suitable in pigs. However, 
The minimization of the embryonic damage and conser-
vation of gene expression with high levels following trans-
fection affects the success of gene editing by CRISPR/
Cas9 system. Therefore, gene editing via the electropora-
tion method may have a benefit as an alternative method 
when the viability of the embryos is a priority.
Limitations
One limitation in this study was that only B4GALNT2 
gene was targeted due to the complicated experimental 
procedures. Different target genes should be compared in 
future studies.
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